Industry News

  • FDA Approves Pembrolizumab for High-Risk, Early-Stage TNBC

    On July 27, 2021, the U.S. Food and Drug Administration (FDA) approved pembrolizumab for the treatment of patients with high-risk, early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment and then continued as a single agent as adjuvant treatment after surgery.

    Read Merck's announcement.

    Posted 7/27/2021



  • FDA Approves Pembrolizumab + Lenvatinib for Advanced Endometrial Cancer

    On July 22, 2021, the U.S. Food and Drug Administration (FDA) approved the combination of pembrolizumab plus lenvatinib for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient, who have disease progression following prior systemic therapy in any setting and who are not candidates for curative surgery or radiation. 

    Read the FDA announcement.

    Read the Merck announcement.

    Read the Eisai Inc. announcement

    Posted 7/22/2021



  • FDA Grants Regular Approval + New Indication to Enfortumab Vedotin-ejfv

    On July 9, 2021, Astellas Pharma Inc. and Seagen Inc. announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to enfortumab vedotin-ejfv. The FDA also approved a new indication for enfortumab vedotin-ejfv for adult patients with locally advanced or metastatic urothelial cancer who are ineligible for cisplatin-containing chemotherapy and who have previously received one or more prior lines of therapy.

    Read the FDA announcement.

    Read the SeaGen announcement.

    Posted 7/9/2021


  • FDA Approves Expanded Indication for Pembrolizumab for cSCC

    On July 6, 2021, the U.S. Food and Drug Administration (FDA) approved an expanded label for pembrolizumab as a monotherapy treatment for patients with locally advanced cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.

    Read Merck's announcement.

    Posted 7/6/2021


  • FDA Approves Component of Chemotherapy Regimen for ALL and LBL

    On June 30, 2021, the U.S. Food and Drug Administration (FDA) approved asparaginase erwinia chrysanthemi (recombinant)-rywn as a component of a multi-agent chemotherapy regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients who are allergic to the E. coli-derived asparaginase products used most commonly for treatment.

    Read the FDA announcement.

    Read the Jazz Pharmaceuticals announcement.

    Posted 7/1/2021


  • Updated Data for Durvalumab

    Durvalumab (Imfinzi®, AstraZeneca) offers the best chance for long-term survival in a curative intent setting. This update comes after the post-hoc analysis of 5-year overall and progression-free survival data had been released for the PACIFIC trial, a large, Phase III, randomized, double-blind, placebo-controlled, multicenter study of 713 patients with unresectable Stage III NSCLC. The primary overall survival analysis was reported at 2 years (25.2 months median follow-up). For more information, click here

    Posted 6/10/2021



  • FDA Approves Sotorasib for KRAS G12C-Mutated NSCLC

    The U.S. Food and Drug Administration (FDA) has approved sotorasib (LUMAKRASTM, Amgen) for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. Sotorasib has received accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

    Read press release.

    Posted on 6/1/2021



  • FDA Approves Nivolumab for Completely Resected Esophageal or GEJ Cancer

    On May 20, 2021, the U.S. Food and Drug Administration (FDA) approved nivolumab for patients with completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease who have received neoadjuvant chemoradiotherapy.

    Read the FDA announcement.

    Read the Bristol Myers Squibb announcement.

    Posted 5/21/2021



  • Positive Phase 3 Cemiplimab Results in Advanced Cervical Cancer

    On Wednesday, May 12, Regeneron Pharmaceuticals, Inc. and Sanofi announced the presentation of positive results from the Phase 3 trial investigating the PD-1 inhibitor cemiplimab (Libtayo®) in patients with recurrent or metastatic cervical cancer who had previously progressed on chemotherapy.

    The data were shared as part of a European Society for Medical Oncology Virtual Plenary and add to previously reported data showing an improvement in overall survival (OS) with Libtayo compared to chemotherapy. The data will form the basis of regulatory submissions in 2021.

    Read the press release.

    Posted on 5/12/2021



  • FDA Approves Pembrolizumab for Esophageal or GEJ Carcinoma

    The Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda®, Merck) for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy.

    Read the prescribing information and medication guide.

    Posted on 4/30/2021




1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
scosonline.com
Email Us